We are deconvoluting the role of the human extracellular matrix (ECM) in healthy and diseased states to uncover new targets for fibrosis and solid tumours and to support the discovery and development of novel classes of therapeutics.
We have pioneered the world’s first human extracellular matrix-based drug discovery platform.
We are developing a portfolio of programmes in fibrosis and solid tumours.
We have significant agreements with Takeda Pharmaceuticals and Dompé farmaceutici.
Our ambitious team has a wealth of technical and medical knowledge and a strong commercial mindset.
Proprietary in vitro 3D tissue specific and disease specific screening
We work with pharma and biotech partners to utilise the full discovery potential of our platform
Learn more